Molecular Epidemiology of Rotavirus Strains in Symptomatic and Asymptomatic Children in Manhiça District, Southern Mozambique 2008-2019.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: MDPI Country of Publication: Switzerland NLM ID: 101509722 Publication Model: Electronic Cited Medium: Internet ISSN: 1999-4915 (Electronic) Linking ISSN: 19994915 NLM ISO Abbreviation: Viruses Subsets: MEDLINE
    • Publication Information:
      Original Publication: Basel, Switzerland : MDPI
    • Subject Terms:
      Molecular Epidemiology*; Rotavirus/*genetics ; Rotavirus Infections/*epidemiology ; Rotavirus Infections/*virology; Case-Control Studies ; Child, Preschool ; Diarrhea/epidemiology ; Diarrhea/virology ; Feces/virology ; Genotype ; Humans ; Infant ; Infant, Newborn ; Mozambique/epidemiology ; Rotavirus Infections/prevention & control ; Rotavirus Vaccines ; Vaccines, Attenuated
    • Abstract:
      Group A rotaviruses remain the leading cause of diarrhoea in children aged <5 years. Mozambique introduced rotavirus vaccine (Rotarix ® ) in September 2015. We report rotavirus genotypes circulating among symptomatic and asymptomatic children in Manhiça District, Mozambique, pre- and post-vaccine introduction. Stool was collected from enrolled children and screened for rotavirus by enzyme-immuno-sorbent assay. Positive specimens were genotyped for VP7 (G genotypes) and VP4 (P genotypes) by the conventional reverse transcriptase polymerase chain reaction. The combination G12P[8] was more frequently observed in pre-vaccine than in post-vaccine introduction, in moderate to severe diarrhoea (34%, 61/177 vs. 0, p < 0.0001) and controls (23%, 26/113 vs. 0, p = 0.0013) and mixed genotypes (36%, 24/67 vs. 7% 4/58, p = 0.0003) in less severe diarrhoea. We observed changes in post-vaccine compared to pre-vaccine introduction, where G3P[4] and G3P[8] were prevalent in moderate to severe diarrhoea (10%, 5/49 vs. 0, p = 0.0002; and 14%, 7/49 vs. 1%, 1/177, p < 0.0001; respectively), and in less severe diarrhoea (21%, 12/58 vs. 0, p = 0.003; and 24%, 14/58 vs. 0, p < 0.0001; respectively). Our surveillance demonstrated the circulation of similar genotypes contemporaneously among cases and controls, as well as switching from pre- to post-vaccine introduction. Continuous surveillance is needed to evaluate the dynamics of the changes in genotypes following vaccine introduction.
    • References:
      Pathogens. 2021 Mar 17;10(3):. (PMID: 33802966)
      Open Virol J. 2014 Dec 11;8:14-9. (PMID: 25553142)
      Epidemiol Infect. 2016 Jul;144(9):1943-50. (PMID: 26743189)
      J Clin Microbiol. 2000 Feb;38(2):898-901. (PMID: 10655412)
      Vaccine. 2018 Nov 12;36(47):7238-7242. (PMID: 29371014)
      Hum Vaccin Immunother. 2012 Apr;8(4):465-9. (PMID: 22370511)
      J Clin Microbiol. 1990 Feb;28(2):276-82. (PMID: 2155916)
      Epidemiol Infect. 2011 Jun;139(6):895-909. (PMID: 20707941)
      Epidemiol Infect. 2020 Oct 01;148:e245. (PMID: 32998792)
      J Med Microbiol. 2017 Feb;66(2):112-118. (PMID: 28051950)
      Vaccine. 2014 Aug 11;32 Suppl 1:A68-74. (PMID: 25091684)
      Vaccine. 2019 Oct 8;37(43):6324-6328. (PMID: 31530468)
      J Clin Microbiol. 2004 Jun;42(6):2541-7. (PMID: 15184432)
      Lancet. 2007 Nov 24;370(9601):1757-63. (PMID: 18037080)
      Euro Surveill. 2019 Feb;24(6):. (PMID: 30755297)
      Infect Genet Evol. 2015 Aug;34:106-13. (PMID: 26079278)
      Pathogens. 2020 Nov 24;9(12):. (PMID: 33255256)
      Int J Epidemiol. 2021 May 17;50(2):395. (PMID: 33452521)
      Infect Genet Evol. 2018 Aug;62:95-108. (PMID: 29656042)
      Int J Infect Dis. 2020 Nov;100:434-440. (PMID: 32898668)
      Niger Postgrad Med J. 2016 Jan-Mar;23(1):1-5. (PMID: 27098941)
      Infect Genet Evol. 2019 Apr;69:68-75. (PMID: 30641151)
      BMC Infect Dis. 2016 Jun 14;16:287. (PMID: 27296987)
      J Infect Dis. 2020 Oct 09;:. (PMID: 33033832)
      Infect Dis Poverty. 2016 Aug 12;5(1):83. (PMID: 27514855)
      BMC Infect Dis. 2020 Aug 12;20(1):596. (PMID: 32787859)
      Arch Virol. 1999;144(5):1027-34. (PMID: 10416384)
      Infect Genet Evol. 2015 Apr;31:321-34. (PMID: 25701122)
      J Med Virol. 2016 Oct;88(10):1751-8. (PMID: 27003797)
      PLoS One. 2014 Dec 01;9(12):e113674. (PMID: 25437502)
      Springerplus. 2016 Jan 29;5:97. (PMID: 26848437)
      Pathogens. 2020 Aug 19;9(9):. (PMID: 32824938)
      BMC Infect Dis. 2019 Apr 15;19(1):322. (PMID: 30987589)
      Virology. 2009 Mar 1;385(1):58-67. (PMID: 19131083)
      PLoS One. 2014 Oct 20;9(10):e110795. (PMID: 25330070)
      Virol J. 2018 Apr 27;15(1):78. (PMID: 29699581)
      Vaccine. 2018 Nov 12;36(47):7222-7230. (PMID: 29203181)
      Pathogens. 2021 Apr 01;10(4):. (PMID: 33915946)
      Lancet. 2013 Jul 20;382(9888):209-22. (PMID: 23680352)
      Lancet Glob Health. 2019 May;7(5):e568-e584. (PMID: 31000128)
      Vaccine. 2014 Aug 11;32 Suppl 1:A62-7. (PMID: 25091683)
      J Med Virol. 2004 May;73(1):118-22. (PMID: 15042658)
      Vaccine. 2019 Aug 23;37(36):5350-5356. (PMID: 31331769)
      Pak J Biol Sci. 2017;20(2):59-69. (PMID: 29022996)
      J Clin Microbiol. 1992 Jun;30(6):1365-73. (PMID: 1320625)
      J Pathog. 2018 Oct 1;2018:6513682. (PMID: 30364038)
      Vaccine. 2014 Aug 11;32 Suppl 1:A129-33. (PMID: 25091666)
      J Infect Dis. 2010 Sep 1;202 Suppl:S49-54. (PMID: 20684717)
      PLoS One. 2015 May 14;10(5):e0119824. (PMID: 25973880)
      J Clin Virol. 2010 Apr;47(4):340-4. (PMID: 20138804)
      JAMA Pediatr. 2018 Oct 1;172(10):958-965. (PMID: 30105384)
      Discov Med. 2012 Jan;13(68):85-97. (PMID: 22284787)
      Arch Virol. 2018 Jan;163(1):153-165. (PMID: 29052059)
      Int J Epidemiol. 2013 Oct;42(5):1309-18. (PMID: 24159076)
      J Biomed Sci. 2020 May 21;27(1):66. (PMID: 32438911)
      Hum Vaccin Immunother. 2017 Mar 4;13(3):711-716. (PMID: 27686522)
    • Grant Information:
      001 International WHO_ World Health Organization
    • Contributed Indexing:
      Keywords: Mozambique; case-control study; genotypes; rotavirus A
    • Accession Number:
      0 (RIX4414 vaccine)
      0 (Rotavirus Vaccines)
      0 (Vaccines, Attenuated)
    • Publication Date:
      Date Created: 20220122 Date Completed: 20220228 Latest Revision: 20220228
    • Publication Date:
      20240105
    • Accession Number:
      PMC8781303
    • Accession Number:
      10.3390/v14010134
    • Accession Number:
      35062336